New combo diabetes pill passes early safety check in healthy people
NCT ID NCT07128654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new combination pill (CTL02) that contains two diabetes drugs (alogliptin and empagliflozin) in a single tablet. Forty healthy adults received either the combo pill or the two drugs separately to compare safety and how the body processes them. The trial is complete and focused on basic safety and drug levels, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTL02 (a fixed-dose combination tablet of alogliptin and empagliflozin)
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H+ Yangji Hospital
Seoul, South Korea